Zydus Lifesciences Limited (ZYDUSLIFE) — Financial Results | 9 February 2026(2 announcements)

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
1 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

Zydus Lifesciences reported Q3 FY26 revenue from operations of ₹68,645 mn, up 30% YoY, with adjusted net profit of ₹11,109 mn, up 9% YoY. For 9M FY26, revenues reached ₹1,95,614 mn, up 17% YoY, and adjusted net profit was ₹38,640 mn, up 15% YoY. EBITDA margins improved to 30.3% (9M, +80 bps YoY). Key drivers included North America formulations growth of 16% YoY, Consumer Wellness surge of 113% YoY, and International Markets formulations up 38% YoY. The company strengthened its innovation pipeline with orphan drug approval and specialty portfolio expansion.

2 Financial Results 🔴 High Importance ✨ Positive 📄 PDF

Zydus Lifesciences reported Q3 FY26 revenues of ₹68,645 million, up 30% YoY, driven by robust pharmaceutical business growth across India formulations (13% YoY), North America (16.4% YoY), and International Markets (38.2% YoY). EBITDA reached ₹18,164 million with margin at 26.5%, up 20 bps YoY. Adjusted net profit grew 8.5% YoY to ₹11,109 million. Consumer Wellness surged 113% YoY following Comfort Click Limited consolidation. Regulatory approvals included Nufymco® biosimilar and Zycubo® for Menkes disease. Net debt improved to ₹28,728 million from negative ₹48,880 million year-ago.

About Zydus Lifesciences Limited (ZYDUSLIFE)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,01,800.69 Cr P/E: 22.5

View full ZYDUSLIFE stock details →

📡 Get AI alerts when ZYDUSLIFE files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ZYDUSLIFE — Free

📊 More ZYDUSLIFE filings

See all ZYDUSLIFE filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ZYDUSLIFE files new disclosures

Track ZYDUSLIFE filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track ZYDUSLIFE — Free

Free account · 2 AI queries/day